Document is current
Any future updates will be listed below
-
Authors
Rius Rigau, Aleix
Xu, Meilin
Liu, Ziyuan
Chenguiti Fakhouri, Sara
Auth, Janina
Garantziotis, Panagiotis
Zoli, Andrea
Selvaraju, Manoj Kumar
Raimondo, Maria Gabriella https://orcid.org/0000-0003-2020-6711
Tur, Carlo https://orcid.org/0009-0003-6241-6116
Filla, Tim
Gehringer, Paula
Eckstein, Markus https://orcid.org/0000-0001-5418-3349
Müller, Fabian https://orcid.org/0000-0001-5487-5839
Atzinger, Armin
Ronicke, Moritz
Ekici, Arif https://orcid.org/0000-0001-6099-7066
Schmid, Rafael
Wirsching, Andreas
Hagen, Melanie
Böltz, Sebastian https://orcid.org/0000-0001-5227-8707
Krickau, Tobias
Horch, Raymund E. https://orcid.org/0000-0002-6561-2353
Berking, Carola https://orcid.org/0000-0003-0229-8931
Grieshaber-Bouyer, Ricardo https://orcid.org/0000-0002-2873-5135
Ramming, Andreas https://orcid.org/0000-0002-7003-501X
Gupta, Pooja https://orcid.org/0009-0009-3328-5157
Bozec, Aline https://orcid.org/0000-0001-8174-2118
Mackensen, Andreas https://orcid.org/0000-0002-0685-4483
Distler, Jörg HW https://orcid.org/0000-0001-7408-9333
Schett, Georg https://orcid.org/0000-0001-8740-9615
Li, Yi-Nan https://orcid.org/0000-0001-8934-9361
Bergmann, Christina https://orcid.org/0000-0001-5257-9171
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70113695)
- License Information
-
More Information
Article History
Received: 17 July 2025
Accepted: 2 April 2026
First Online: 23 May 2026
Competing interests
: J.H.W.D. has consulted for Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Callidatas, Calluna, Galapagos, GSK, Janssen, Kyverna, Novartis, Pfizer, Quell Therapeutics and UCB; has received research funding from Anamar, ARXX, BMS, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, Exo Therapeutics, Galapagos, GSK, Incyte, Inventiva, Kiniksa, Kyverna, Lassen Therapeutics, Mestag, Sanofi-Aventis, SpicaTx, RedX, UCB and ZenasBio; is the CEO of 4D Science and scientific lead of FibroCure. JA was supported by the Kyverna Therapeutics Travel. CB received speaker fees from Novartis. The other authors declare no competing interests.
